A new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant Sciences came to fruition as 2019 drew to a close. The $3 billion transaction announced earlier this year involves the transfer of…
Acceleron and Fulcrum Strike Deal to Address Pulmonary Diseases
Acceleron Pharma and Fulcrum Therapeutics are entering 2020 as partners to tackle pulmonary diseases. On Monday, the two companies forged a collaboration and license agreement that has the potential to be worth more than $450 million. The Cambridge, Mass.-based companies…
Medtech manufacturing lags pharma in emerging markets, McKinsey report says
Dive Brief: Most medtech companies are struggling with expensive and fragmented manufacturing and distribution footprints, often due to growth through acquisitions, according to a new analysis by McKinsey. Manufacturers facing pressure from rising operational costs and demand for increased services…
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
TOKYO and SOUTH SAN FRANCISCO, Calif., Dec. 26, 2019 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James Knighton, “Xyphos”) today announced that Astellas has acquired Xyphos. With the acquisition Astellas will gain…
Cyclo Therapeutics Signs Master Services Agreement with Worldwide Clinical Trials
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has signed a Master Services Agreement with Worldwide Clinical Trials (Worldwide),…
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval
Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn’s Disease and Psoriatic Arthritis FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo,…
Roche and Sarepta Partner on Duchenne Muscular Dystrophy Therapy
Sarepta Therapeutics and Roche inked a licensing deal that gives Roche exclusive commercial rights to SRP-9001, Sarepta’s investigation gene therapy for Duchenne muscular dystrophy (DMD), outside the U.S. DMD is a muscle wasting disease caused by mutations in the dystrophin…
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
First Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug Conjugate targeting Globo H, a glycolipid antigen found on multiple tumor types TAIPEI, Taiwan, Dec. 26, 2019 /PRNewswire/ — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced…
Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance
Pfizer continues to bet on JAK inhibitors. This morning, the company entered into a licensing agreement with Theravance Biopharma for a preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized. Pfizer handed over $10 million…
Atopic Dermatitis Space Will Heat Up in 2020, Analyst Predicts
The future of the atopic dermatitis space is going to be a competitive one. Multiple assets are in line to be submitted for regulatory approval and will, if approved, challenge the leading market share currently held by Regeneron and Sanofi’s…
